1. 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Issue 3 (September 2015) Authors: Vansteenkiste, J.; Fehrenbacher, L.; Spira, A.I.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C.; Braiteh, F.; Yi, J.; He, P.; Kowanetz, M.; Waterkamp, D.; Ballinger, M.; Chen, D.S.; Sandler, A.; Rittmeyer, A. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S716 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT‐301, A NOVEL PYRROLOBENZODIAZAPINE‐BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON‐HODGKIN LYMPHOMA. (June 2017) Authors: Horwitz, S.M.; Fanale, M.A.; Spira, A.I.; Havenith, K.; He, S.; Feingold, J.M.; Hamadani, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 270 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation. (October 2020) Authors: Jänne, P.A.; Rybkin, I.I.; Spira, A.I.; Riely, G.J.; Papadopoulos, K.P.; Sabari, J.K.; Johnson, M.L.; Heist, R.S.; Bazhenova, L.; Barve, M.; Pacheco, J.M.; Leal, T.A.; Velastegui, K.; Cornelius, C.; Olson, P.; Christensen, J.G.; Kheoh, T.; Chao, R.C.; Ou, S.H.I. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST‐IN‐CLASS ANTI‐CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO‐001, IN ADVANCED B‐CELL MALIGNANCIES. (12th June 2019) Authors: Molina, A.; Shah, N.; Krishnan, A.Y.; Shah, N.D.; Burke, J.M.; Melear, J.M.; Spira, A.I.; Popplewell, L.L.; Andreadis, C.B.; Chhabra, S.; Sharman, J.P.; Kaufman, J.L.; Cohen, J.B.; Niesvizky, R.; Martin, T.G.; DiLea, C.; Kuriakose, J.; Matheny, S.L.; Leonard, J.P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 324 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors. (October 2022) Authors: Drilon, A.; Besse, B.; Camidge, D.R.; Ou, S.H.I.; Gadgeel, S.M.; Johnson, M.L.; Calles, A.; de Miguel, M.J.; Spira, A.I.; Felip, E.; Lopes, G.; van der Wekken, A.J.; Elamin, Y.Y.; Green, J.; Sun, Y.; Soglia, J.; Zhu, V.W.; Lin, J.J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗